Microsoft is rolling out a new update for Alpha Skip-Ahead Xbox Insider members that enhances the Quick Resume feature on Xbox Series X|S consoles.

Microsoft is rolling out a new update for Alpha Skip-Ahead Xbox Insider members that enhances the Quick Resume feature on Xbox Series X|S consoles.
It adds in some smartwatch-like functionality without going overboard.
In this guide, we’ll provide a look at how to expand your virtual desktop across multiple screens for desktops and laptops. We also explain various connectors.
Definitive answers to the big questions.
As opposition mounts to the new breakaway European soccer league, Paris St.-Germain joined other top teams in saying it wouldn’t take part.
A new study at Tel Aviv University found that the British variant (termed: B.1.1.7) of COVID-19 is 45% more contagious than the original virus. The researchers relied on data from about 300,000 PCR tests for COVID-19 obtained from the COVID-19 testing lab, which was established in collaboration with the Electra Group.
Researchers at Beam Therapeutics have developed a redesigned base editor that shows considerable promise in directly repairing the single-base mutation that causes sickle-cell disease (SCD). Many strategies are being pursued to harness genome editing approaches including CRISPR to treat patients with SCD and related hemoglobinopathies. The most advanced method in the clinic involves targeting an …
People living with human immunodeficiency virus (HIV) and without known cardiovascular disease have two to three times the noncalcified coronary plaque burden of non-HIV healthy volunteers, according to a study from Canada published in Radiology. Researchers said the results underscore the importance of a heart-healthy lifestyle in people living with HIV.
As of Monday, every American aged 16 or older in all 50 states is now open to receive the COVID-19 vaccine, meeting President Joe Biden’s promise to deliver vaccines to all adults by April 19.
A cutting-edge experimental drug cuts nearly in half the risk of death among patients with a rare but aggressive cancer of the eye, new clinical trial data show.